skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Lacosamide for the prevention of partial onset seizures in epileptic adults

Review

(1940) Views  (558) Full article downloads

Authors: Anna Kelemen, Péter Halász

Published Date July 2010 Volume 2010:6(1) Pages 465 - 471
DOI: http://dx.doi.org/10.2147/NDT.S7967

Anna Kelemen1, Péter Halász2

1National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, Pázmány Péter Catholic University, Budapest, Hungary

Abstract: Lacosamide is a newly registered antiepileptic drug with dual mechanisms of action. It selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It also binds to a collapsing-response mediator protein-2, CRMP2. Lacosamide has a favorable pharmacokinetic profile; is rapidly and completely absorbed, has a relatively long elimination half-life of 13 hours which allows twice-daily administration, linear pharmacokinetics, and has low potential for drug interactions and renal elimination. Both oral and intravenous formulations of lacosamide are being developed. In placebo-controlled clinical trials, lacosamide was effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures. Lacosamide was generally well tolerated. The most frequently reported adverse events in placebo-controlled trials were dizziness, headache, nausea, and diplopia. Intravenous lacosamide has a comparably good safety profile.

Keywords: lacosamide, epilepsy, partial onset seizures






Readers of this article also read:

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
Depressive and adjustment disorders – some questions about the differential diagnosis: case studies
Current and emerging treatment options in the management of Friedreich ataxia
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Clinical utility of adjunctive retigabine in partial onset seizures in adults